M&A Deal Summary |
|
|---|---|
| Date | 2019-04-26 |
| Target | Aratana Therapeutics |
| Sector | Life Science |
| Buyer(s) | Elanco |
| Deal Type | Add-on Acquisition |
| Deal Value | 245M USD |
| Advisor(s) | Barclays Investment Bank (Financial) Latham & Watkins (Legal) |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 1954 |
| Sector | Life Science |
| Employees | 9,000 |
| Revenue | 4.4B USD (2024) |
Elanco develops and markets products and services to improve animal health and protein production in more than 75 countries. Elanco was incorporated in 1954 and is based in Greenfield, Indiana.
| DEAL STATS | # |
|---|---|
| Overall | 8 of 11 |
| Sector: Life Science M&A | 5 of 7 |
| Type: Add-on Acquisition M&A Deals | 4 of 6 |
| State: Kansas M&A | 1 of 1 |
| Country: United States M&A | 5 of 6 |
| Year: 2019 M&A | 1 of 3 |
| Size (of disclosed) | 5 of 5 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2016-10-05 |
Boehringer Ingelheim Vetmedica - U.S. Feline Canine and Rabies Vaccines
St. Joseph, Montana, United States Boehringer Ingelheim Vetmedica, Inc. - U.S. Feline, Canine and Rabies Vaccines is a developer of vaccines for animals. The business also inculded fully integrated manufacturing and R&D site. |
Buy | $885M |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2019-08-01 |
Prevtec Microbia
Montreal, Quebec, Canada Prevtec Microbia, Inc. is a Canadian biotechnology company developing and commercializing sustainable solutions as alternatives to antibiotics to improve animal health, production performance and food safety. Prevtec Microbia’s first commercial product, Coliprotec®F4, a swine E. coli vaccine, has been sold across Canada since 2007 and in the EU since 2015, and is approved in Brazil (2010) and in the US (2018). |
Buy | - |
